Ocular Imaging With Spectral Domain Optical Coherence Tomography

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by Yonsei University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Yonsei University
ClinicalTrials.gov Identifier:
NCT00926549
First received: May 6, 2009
Last updated: June 19, 2009
Last verified: June 2009

May 6, 2009
June 19, 2009
May 2009
September 2009   (final data collection date for primary outcome measure)
macular retinal thickness and volume [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00926549 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Ocular Imaging With Spectral Domain Optical Coherence Tomography
Posterior and Anterior Ocular Imaging With Spectral Domain Optical Coherence Tomography

The purpose of this study is to analyze macular retinal thickness and macular volume using the spectral domain - optical coherence tomography (SD-OCT) in normal eyes and in eyes with various ocular diseases.

Assessment of macular thickness is important for the treatment and follow-up of a variety of ocular diseases. The introduction of optical coherence tomography (OCT) has enabled clinicians to reliably detect small changes in macular thickness and to quantitatively evaluate the efficacy of different therapeutic modalities. In this study using the spectral domain-OCT, we examined the variations of macular retinal thickness and macular volume in normal eyes and in eyes with various ocular diseases.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Healthy
  • Myopia
  • Hypermetropia
Device: Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)
macular cube scanning
Other Name: Cirrus™ HD-OCT, Carl Zeiss Meditec AG
Experimental: spectral domain-OCT
Spectral domain-OCT scanning performed.
Intervention: Device: Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
September 2009
September 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • normal eyes
  • myopic eyes
  • hypermetropic eyes

Exclusion Criteria:

  • systemic illness
  • cataract
  • previous ocular trauma or surgery(other than cataract surgery or refractive surgeries)
Both
16 Years to 85 Years
Yes
Contact: Sung Soo Kim, MD, PhD 82-2-2019-3443 semekim@naver.com
Contact: Won Kyung Song, MD 82-2-2228-3591 songwk@yuhs.ac
Korea, Republic of
 
NCT00926549
3-2008-0048
Yes
Sung Soo Kim, Department of Ophthalmology, Gangnam Severance Hospital
Yonsei University
Not Provided
Principal Investigator: Sung Soo Kim, MD, PhD Department of Ophthalmology, Yonsei University College of Medicine, Gangnam Severance Hospital
Yonsei University
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP